Dyne Therapeutics, Inc. $DYN Stake Reduced by Siren L.L.C.

Siren L.L.C. cut its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 36.4% during the 1st quarter, Holdings Channel.com reports. The fund owned 2,229,125 shares of the company’s stock after selling 1,273,816 shares during the quarter. Dyne Therapeutics accounts for about 1.1% of Siren L.L.C.’s portfolio, making the stock its 26th biggest position. Siren L.L.C.’s holdings in Dyne Therapeutics were worth $40,414,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of DYN. Creative Planning grew its stake in shares of Dyne Therapeutics by 6.8% in the 3rd quarter. Creative Planning now owns 15,527 shares of the company’s stock worth $196,000 after purchasing an additional 986 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Dyne Therapeutics by 26.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock valued at $136,000 after purchasing an additional 1,440 shares during the last quarter. Hilton Head Capital Partners LLC acquired a new stake in Dyne Therapeutics during the first quarter valued at approximately $26,000. Caxton Associates LLP boosted its holdings in Dyne Therapeutics by 10.9% during the second quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock worth $158,000 after buying an additional 1,627 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its holdings in Dyne Therapeutics by 102.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after buying an additional 2,465 shares in the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Stock Performance

Dyne Therapeutics stock opened at $23.89 on Friday. Dyne Therapeutics, Inc. has a fifty-two week low of $8.88 and a fifty-two week high of $25.00. The firm’s 50 day simple moving average is $20.24 and its 200-day simple moving average is $18.57. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92. The company has a market cap of $3.95 billion, a P/E ratio of -7.42 and a beta of 1.06.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same quarter in the previous year, the company posted ($1.05) earnings per share. As a group, equities research analysts predict that Dyne Therapeutics, Inc. will post -3.02 EPS for the current year.

Insider Buying and Selling at Dyne Therapeutics

In other news, CFO Erick Lucera sold 2,362 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $20.37, for a total value of $48,113.94. Following the completion of the sale, the chief financial officer owned 121,563 shares of the company’s stock, valued at $2,476,238.31. This trade represents a 1.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Brian S. Posner purchased 2,000 shares of the stock in a transaction dated Monday, June 8th. The shares were acquired at an average price of $16.94 per share, for a total transaction of $33,880.00. Following the acquisition, the director directly owned 24,500 shares of the company’s stock, valued at $415,030. This represents a 8.89% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have bought 9,000 shares of company stock valued at $156,800 and have sold 2,066,372 shares valued at $43,648,928. Company insiders own 9.46% of the company’s stock.

Analyst Ratings Changes

DYN has been the topic of several research reports. Wall Street Zen raised Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, July 6th. Cantor Fitzgerald assumed coverage on Dyne Therapeutics in a research note on Thursday. They set an “overweight” rating for the company. TD Cowen started coverage on Dyne Therapeutics in a report on Friday, June 26th. They issued a “buy” rating on the stock. Sanford C. Bernstein boosted their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Finally, Evercore set a $33.00 target price on Dyne Therapeutics in a report on Friday, May 15th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Dyne Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $34.17.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.